Rigel Pharmaceuticals (RIGL)

Add to Watchlists
Create an Alert
3.42 +0.23  +7.38% NASDAQ Apr 22, 8:00PM BATS Real time Currency in USD
View Full Chart
RIGL Price Chart
View All Events

RIGL Events

Date Type Description
Mar 04 Earnings Q4 2013 Rigel Earnings Results. Estimate: -0.24.
Nov 05 Earnings Rigel Announces Third Quarter 2013 Financial Results. Estimate: -0.28.
Aug 06 Earnings Rigel Announces Second Quarter 2013 Financial Results. Estimate: -0.31.
May 07 Earnings Rigel Announces First Quarter 2013 Financial Results. Estimate: -0.30.
View All Performance Charts

RIGL Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Rigel Pharmaceuticals is down 28.00% over the last year vs S&P 500 Total Return up 23.42%, AstraZeneca up 36.48%, and Lannett up 249.8%.

Get Quote for

Portfolio Strategies Featuring RIGL

Did Rigel Pharmaceuticals make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

RIGL Profile

  • Sector: Healthcare
  • Industry: Drug Manufacturers - Specialty & Generic
  • Headquarters Country: United States
  • Headquarters State/Province: California
  • Incorporation Country: United States
  • Incorporation State/Province: Delaware
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: December 31, 2014
  • Last Fiscal Quarter End: December 31, 2013
  • Last Fiscal Year End: December 31, 2013
  • NAICS: Pharmaceutical Preparation Manufacturing
  • NAICS Code: 325412
  • NAICS Industry: Pharmaceutical and Medicine Manufacturing
  • NAICS Industry Code: 3254
  • NAICS Sector: Manufacturing
  • NAICS Sector Code: 32

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis, R343, an inhaled SYK inhibitor that has completed Phase 1 clinical trials for asthma, R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders, and R333, a topical JAK/SYK inhibitor for the treatment of discoid lupus. Rigel Pharmaceuticals, Inc. has collaboration agreements with AstraZeneca AB; Pfizer, Inc.; and Daiichi Pharmaceuticals Co., Ltd. The company was founded by Donald G. Payan, Garry P. Nolan and Ronald B. Garren on June 14,1996 and is based in South San Francisco, California.

Recent Quotes

Symbol Price Chg Chg % Market Cap
RIGL 3.42 +0.23 +7.38% 299.33M
Create Watchlist from Quotes

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

Get Started Now

Upgrade to {{root.upsell.info.tier_name}}. Start Your YCharts Membership. Start your {{root.upsell.info.tier_name}} Membership


{{root.upsell.info.is_upgrade ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{root.upsell.info.tier_name}} Member? Sign in here.